Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05364879
Other study ID # NSH Adv Ovarian Cancer Prehab
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 3, 2023
Est. completion date August 31, 2025

Study information

Verified date March 2024
Source Nova Scotia Health Authority
Contact Scott Grandy, PhD
Phone 902-494-1145
Email grandy@dal.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Individuals with ovarian cancer have very poor survival rates. This is because the cancer is not usually detected until it has reached advanced stages. How long an individual survives also is determined by the cancer treatment they receive. Although there are best treatment practices to improve survival, some women have other conditions that limit treatment options. One such condition seen in as many as 50% of women with advanced ovarian cancer is frailty (an age-related decline in function and health). This is a major concern as doctors will often have to change how the cancer is treated based on the patient being frail. For example, patients living with frailty are less likely to have their full tumor removed during surgery. They are also more likely to have complications with surgery, stay in the hospital longer, and recover less well from surgery overall. Patients living with frailty also are more likely to experience delays in their chemotherapy starting, receive lower doses of chemotherapy and/or receive fewer cycles of chemotherapy. These changes in treatment may decrease how long a patient survives after diagnosis. Thus, research is needed to explore strategies to decrease frailty in patients who require treatment for advanced ovarian cancer. An option gaining more attention is physical exercise (e.g. walking, repeatedly rising from a chair). Exercise performed before surgery, which is called prehabilitation, can improve how well a patient recovers after surgery and increase how long they survive. Research has shown that prehabilitation is very beneficial for patients undergoing surgery for heart disease. However, it is not clear whether prehabilitation works for those with advanced ovarian cancer that are going to have surgery. Therefore, the investigators want to explore how a 4+ week exercise program performed while waiting for surgery for advanced ovarian cancer changes frailty and how a patient recovers after surgery. The investigators will specifically look whether the exercise program: 1) reduces how frail a patient is before surgery; 2) improves how well the patient recovers after surgery; and 3) affects the patient's chemotherapy treatment plan. This study will provide important information about the ability of prehabilitation exercise to improve surgical and treatment outcomes in women with advanced ovarian cancer. Overall, it is believed that exercise has the potential to improve the survival of advanced ovarian cancer patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date August 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Have a confirmed diagnosis of stage III or IV ovarian cancer - Scheduled to receive cytoreductive surgery as part of their treatment plan - Must have a minimum of 4-weeks between the time of study enrollment and scheduled surgery - Be able to attend in-person and/or virtual exercise sessions - Be fluent in English - Have oncologist approval Exclusion Criteria: - Have already completed surgery - Unstable cardiac or respiratory disease, injury or any other co-morbid disease that may make it unsafe for participants to exercise - Significant cognitive impairment (e.g., do not have the capacity to consent, unable to follow exercise instructions)

Study Design


Intervention

Behavioral:
Prehabilitation Exercise Intervention
The exercise intervention will consist of light-to-moderate intensity aerobic, resistance, and mobility exercises. These exercises will be performed in a circuit type manner. Participants will perform similar exercises that are modified to meet their individual abilities. Exercise intensity, modifications and substitutions will be determined for each participant based on their medical history, 6 minute walk test results, and baseline frailty scores. Exercise sessions will be performed 3x/wk beginning at 30 min and progressing to 60-min as tolerated for a minimum of four weeks but will continue up until the time of the participants surgery. A hybrid approach will be used for the exercise sessions whereby the participant must attend the first exercise session in person and subsequent sessions will be delivered virtually. Sessions will be overseen by the study Clinical Exercise Physiologist.

Locations

Country Name City State
Canada Nova Scotia Health Halifax Nova Scotia (NS)

Sponsors (2)

Lead Sponsor Collaborator
Nova Scotia Health Authority Dalhousie University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Study Feasibility - Participant Accrual Participant accrual calculated as % of patients referred divided by number of patients consented to participation Throughout study completion, about 2 years
Other Study Feasibility - Participant Attrition Participant attrition calculated as % of consented patients who complete a minimum of 4 weeks of pre-surgical exercise divided by number who withdraw Through study completion, about 2 years
Other Study Feasibility - Participant Adherence Participant program adherence calculated as % of minimum number of exercise sessions completed (e.g., 3 sessions/week for a minimum of 4 weeks for a total of 12 sessions) divided by total number of available exercise sessions over 12-week intervention Throughout study completion, about 2 years
Other Adverse Events All exercise-related adverse and serious adverse will be recorded Throughout study completion, about 2 years
Primary Frailty Change (baseline to post exercise intervention) Frailty will be assessed using the Clinical Frailty Scale (CFS). The CFS is a The CFS is a 9-point scale (1 - very fit, through very severely frail to 9 - terminally ill) developed for healthcare professionals to summarize the overall level of fitness/frailty of an individual. The CFS covers domains of mobility, energy, physical activity, and function. The higher the score on the CFS the more frail/less fit an individual is. Change from baseline to end of 4+ week intervention (pre-surgery)
Primary Frailty Change (baseline to 1-month post surgery) Frailty will be assessed using the Clinical Frailty Scale (CFS). The CFS is a The CFS is a 9-point scale (1 - very fit, through very severely frail to 9 - terminally ill) developed for healthcare professionals to summarize the overall level of fitness/frailty of an individual. The CFS covers domains of mobility, energy, physical activity, and function. The higher the score on the CFS the more frail/less fit an individual is. Change from baseline to about 1-month post-surgery
Primary Frailty Change (baseline to 3-months post surgery) Frailty will be assessed using the Clinical Frailty Scale (CFS). The CFS is a The CFS is a 9-point scale (1 - very fit, through very severely frail to 9 - terminally ill) developed for healthcare professionals to summarize the overall level of fitness/frailty of an individual. The CFS covers domains of mobility, energy, physical activity, and function. The higher the score on the CFS the more frail/less fit an individual is. Change from baseline to about 3-month post-surgery
Primary Surgical Complexity Score (1-month post surgery) Surgical complexity will be assessed based on Enhanced Recovery After Surgery (ERAS) guidelines. Complexity scores will be interpreted as "low" (3 or fewer points), "intermediate" (4-7 points), and "high" (8 or more points). Surgical complexity will be assessed about 1-month post-surgery.
Primary Post-Surgical Outcomes (1-month post surgery) Post-surgical outcomes will be assessed based on Enhanced Recovery After Surgery (ERAS) guidelines. Specific outcomes will include post-op glucose control, analgesia usage, pain, daily weight, early mobilization, and post-operative complications. Post-surgical outcomes will be assessed about 1-month post-surgery.
Primary Surgical Complications (1-month post surgery) Surgical complications will be assessed based on Enhanced Recovery After Surgery (ERAS) guidelines. Specific outcomes will include length of hospital stay and number of readmissions. Surgical complications will be assessed post-surgery about 1-month post-surgery.
Primary Chemotherapy completion rates (End of Cycle 1) Chemotherapy completion rates will be examined through documentation of total drug dose received, changes in dose, cycle delays, and/or discontinuation of treatment At the end of cycle 1 (each cycle is 3 weeks). Immediately after the procedure.
Primary Chemotherapy completion rates (End of Cycle 2) Chemotherapy completion rates will be examined through documentation of total drug dose received, changes in dose, cycle delays, and/or discontinuation of treatment At the end of cycle 2 (each cycle is 3 weeks). Immediately after the procedure.
Primary Chemotherapy completion rates (End of Cycle 3) Chemotherapy completion rates will be examined through documentation of total drug dose received, changes in dose, cycle delays, and/or discontinuation of treatment At the end of cycle 3 (each cycle is 3 weeks). Immediately after the procedure.
Primary Chemotherapy completion rates (End of Cycle 4) Chemotherapy completion rates will be examined through documentation of total drug dose received, changes in dose, cycle delays, and/or discontinuation of treatment At the end of cycle 4 (each cycle is 3 weeks). Immediately after the procedure.
Primary Chemotherapy completion rates (End of Cycle 5) Chemotherapy completion rates will be examined through documentation of total drug dose received, changes in dose, cycle delays, and/or discontinuation of treatment At the end of cycle 5 (each cycle is 3 weeks). Immediately after the procedure.
Primary Chemotherapy completion rates (End of Cycle 6) Chemotherapy completion rates will be examined through documentation of total drug dose received, changes in dose, cycle delays, and/or discontinuation of treatment At the end of cycle 6 (each cycle is 3 weeks). Immediately after the procedure.
Secondary Body Mass Index Change (baseline to post exercise intervention) Weight (kg) and height (m) will be used to calculate BMI Change in BMI from baseline to post 4+ week exercise intervention
Secondary Body Mass Index Change (baseline to 1-month post surgery) Weight (kg) and height (m) will be used to calculate BMI Change in BMI from baseline to about 1-month post surgery.
Secondary Body Mass Index Change (baseline to 3-months post surgery) Weight (kg) and height (m) will be used to calculate BMI Change in BMI from baseline to about 3-month post surgery.
Secondary Aerobic Fitness Change (baseline to post exercise intervention) The six-minute walk will be used to calculate aerobic fitness Change in aerobic fitness from baseline to post 4+ week intervention (pre-surgery)
Secondary Aerobic Fitness Change (baseline to 1-month post surgery) The six-minute walk will be used to calculate aerobic fitness Change in aerobic fitness from baseline to about 1-month post surgery
Secondary Aerobic Fitness Change (baseline to 3-months post surgery) The six-minute walk will be used to calculate aerobic fitness Change in aerobic fitness from baseline to about 3-months post surgery
Secondary Muscular Fitness Change (baseline to post exercise intervention) Muscular fitness will be assessed using the Canadian Society of Exercise Physiology's Physical Activity Training Protocol (CSEP-PATH) and will include the timed sit-to-stand and grip strength. Change in muscular fitness will be assessed from baseline to post exercise intervention (pre-surgery)
Secondary Muscular Fitness Change (baseline to about 1-month post surgery) Muscular fitness will be assessed using the Canadian Society of Exercise Physiology's Physical Activity Training Protocol (CSEP-PATH) and will include the timed sit-to-stand and grip strength. Change in muscular fitness will be assessed from baseline to 1-month post surgery.
Secondary Muscular Fitness Change (baseline to about 3-months post surgery) Muscular fitness will be assessed using the Canadian Society of Exercise Physiology's Physical Activity Training Protocol (CSEP-PATH) and will include the timed sit-to-stand and grip strength. Change in muscular fitness will be assessed from baseline to 3-months post surgery.
Secondary Health-Related Quality of Life Change (baseline to post exercise intervention Health-related quality of life will be assess using the EuroQoL five dimensional questionnaire (EQ-5D-5L). The EQ-5D-DL measures mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; higher scores indicate higher problems Chang in health-related quality of life from baseline to post 4+ week intervention (pre-surgery)
Secondary Health-Related Quality of Life Change (baseline to 1-month post surgery) Health-related quality of life will be assess using the EuroQoL five dimensional questionnaire (EQ-5D-5L). The EQ-5D-DL measures mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; higher scores indicate higher problems Chang in health-related quality of life from baseline to about 1-month post surgery
Secondary Health-Related Quality of Life Change (baseline to 3-months post surgery) Health-related quality of life will be assess using the EuroQoL five dimensional questionnaire (EQ-5D-5L). The EQ-5D-DL measures mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; higher scores indicate higher problems Change in health-related quality of life from baseline to about 3-months post surgery
Secondary Physical, Functional, Emotional, and Social/Family Quality of Life Change (baseline to post exercise intervention) The Functional Assessment of Cancer Therapy for Ovarian Cancer (FACT-O) will be used to measure cancer-specific quality of life; 27-item questionnaire with higher scores indicating higher overall quality of life. Change in FACT-O from baseline to post 4+ week intervention (pre-surgery)
Secondary Physical, Functional, Emotional, and Social/Family Quality of Life Change (baseline to 1-month post surgery) The Functional Assessment of Cancer Therapy for Ovarian Cancer (FACT-O) will be used to measure cancer-specific quality of life; 27-item questionnaire with higher scores indicating higher overall quality of life. Change in FACT-O from baseline to about 1-month post surgery
Secondary Physical, Functional, Emotional, and Social/Family Quality of Life Change (baseline to 3-months post surgery) The Functional Assessment of Cancer Therapy for Ovarian Cancer (FACT-O) will be used to measure cancer-specific quality of life; 27-item questionnaire with higher scores indicating higher overall quality of life. Change in FACT-O from baseline to about 3-months post surgery
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2

External Links